Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

Davidson M, Aronson LI, Howard-Reeves J, Bryant H, Cutts RJ, Hulkki-Wilson S, Kouvelakis K, Kalaitzaki E, Watkins D, Starling N, Rao S, Cardenosa ML, Begum R, Rana I, Lazaro-Alcausi R, Terlizzo M, Wotherspoon A, Brown G, Swansbury J, Lord CJ, Cunningham D, Chau I, Chong IY.

Eur J Cancer. 2019 Oct 10;122:12-21. doi: 10.1016/j.ejca.2019.09.003. [Epub ahead of print]

PMID:
31606655
2.

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE.

Clin Cancer Res. 2018 May 15;24(10):2395-2407. doi: 10.1158/1078-0432.CCR-17-1594. Epub 2018 Feb 1.

3.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

4.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

5.

A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex.

Mirabella F, Murison A, Aronson LI, Wardell CP, Thompson AJ, Hanrahan SJ, Fok JH, Pawlyn C, Kaiser MF, Walker BA, Davies FE, Morgan GJ.

PLoS One. 2014 Jun 12;9(6):e99493. doi: 10.1371/journal.pone.0099493. eCollection 2014.

6.

The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.

Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE.

Oncotarget. 2015 Jul 10;6(19):17314-27.

7.

Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress.

Zhang L, Fok JJ, Mirabella F, Aronson LI, Fryer RA, Workman P, Morgan GJ, Davies FE.

Cancer Lett. 2013 Oct 1;339(1):49-59. doi: 10.1016/j.canlet.2013.07.023. Epub 2013 Jul 22.

8.

Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application.

Aronson LI, Davenport EL, Mirabella F, Morgan GJ, Davies FE.

Leukemia. 2013 Dec;27(12):2397-403. doi: 10.1038/leu.2013.150. Epub 2013 May 14. No abstract available.

9.

DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Aronson LI, Davies FE.

Haematologica. 2012 Aug;97(8):1119-30. doi: 10.3324/haematol.2012.064923. Epub 2012 May 11. Review.

10.

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma.

Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D, Smith EM, Powers MV, Sharp SY, Workman P, Morgan GJ, Davies FE.

Leukemia. 2010 Oct;24(10):1804-7. doi: 10.1038/leu.2010.168. Epub 2010 Aug 12. No abstract available.

PMID:
20703255
11.

Starving to succeed.

Davenport EL, Aronson LI, Davies FE.

Autophagy. 2009 Oct;5(7):1052-4. Epub 2009 Oct 14. No abstract available.

PMID:
19652531

Supplemental Content

Loading ...
Support Center